152 related articles for article (PubMed ID: 16260160)
1. Structure-based drug design to the discovery of new 2-aminothiazole CDK2 inhibitors.
Vulpetti A; Casale E; Roletto F; Amici R; Villa M; Pevarello P
J Mol Graph Model; 2006 Mar; 24(5):341-8. PubMed ID: 16260160
[TBL] [Abstract][Full Text] [Related]
2. Differential binding of inhibitors to active and inactive CDK2 provides insights for drug design.
Kontopidis G; McInnes C; Pandalaneni SR; McNae I; Gibson D; Mezna M; Thomas M; Wood G; Wang S; Walkinshaw MD; Fischer PM
Chem Biol; 2006 Feb; 13(2):201-11. PubMed ID: 16492568
[TBL] [Abstract][Full Text] [Related]
3. Structure-based discovery and optimization of potential cancer therapeutics targeting the cell cycle.
Thomas MP; McInnes C
IDrugs; 2006 Apr; 9(4):273-8. PubMed ID: 16596481
[TBL] [Abstract][Full Text] [Related]
4. Searching for cyclin-dependent kinase inhibitors using a new variant of the cope elimination.
Griffin RJ; Henderson A; Curtin NJ; Echalier A; Endicott JA; Hardcastle IR; Newell DR; Noble ME; Wang LZ; Golding BT
J Am Chem Soc; 2006 May; 128(18):6012-3. PubMed ID: 16669651
[TBL] [Abstract][Full Text] [Related]
5. Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors.
McInnes C; Wang S; Anderson S; O'Boyle J; Jackson W; Kontopidis G; Meades C; Mezna M; Thomas M; Wood G; Lane DP; Fischer PM
Chem Biol; 2004 Apr; 11(4):525-34. PubMed ID: 15123247
[TBL] [Abstract][Full Text] [Related]
6. Quantitative evaluation of each catalytic subsite of cathepsin B for inhibitory activity based on inhibitory activity-binding mode relationship of epoxysuccinyl inhibitors by X-ray crystal structure analyses of complexes.
Watanabe D; Yamamoto A; Tomoo K; Matsumoto K; Murata M; Kitamura K; Ishida T
J Mol Biol; 2006 Oct; 362(5):979-93. PubMed ID: 16950396
[TBL] [Abstract][Full Text] [Related]
7. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
[TBL] [Abstract][Full Text] [Related]
8. Structure-based drug design of a highly potent CDK1,2,4,6 inhibitor with novel macrocyclic quinoxalin-2-one structure.
Kawanishi N; Sugimoto T; Shibata J; Nakamura K; Masutani K; Ikuta M; Hirai H
Bioorg Med Chem Lett; 2006 Oct; 16(19):5122-6. PubMed ID: 16876403
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexes.
Andrews MJ; McInnes C; Kontopidis G; Innes L; Cowan A; Plater A; Fischer PM
Org Biomol Chem; 2004 Oct; 2(19):2735-41. PubMed ID: 15455144
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of the Plasmodium falciparum PK5 ATP-binding site: implications for the design of novel antimalarial agents.
Keenan SM; Welsh WJ
J Mol Graph Model; 2004 Jan; 22(3):241-7. PubMed ID: 14629982
[TBL] [Abstract][Full Text] [Related]
11. Protein structures in virtual screening: a case study with CDK2.
Thomas MP; McInnes C; Fischer PM
J Med Chem; 2006 Jan; 49(1):92-104. PubMed ID: 16392795
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological activity of new CDK4-specific inhibitors, based on fascaplysin.
Aubry C; Wilson AJ; Jenkins PR; Mahale S; Chaudhuri B; Maréchal JD; Sutcliffe MJ
Org Biomol Chem; 2006 Mar; 4(5):787-801. PubMed ID: 16493461
[TBL] [Abstract][Full Text] [Related]
13. Dissecting the determinants of cyclin-dependent kinase 2 and cyclin-dependent kinase 4 inhibitor selectivity.
Pratt DJ; Bentley J; Jewsbury P; Boyle FT; Endicott JA; Noble ME
J Med Chem; 2006 Sep; 49(18):5470-7. PubMed ID: 16942020
[TBL] [Abstract][Full Text] [Related]
14. Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: protein structure-guided design and SAR.
Richardson CM; Williamson DS; Parratt MJ; Borgognoni J; Cansfield AD; Dokurno P; Francis GL; Howes R; Moore JD; Murray JB; Robertson A; Surgenor AE; Torrance CJ
Bioorg Med Chem Lett; 2006 Mar; 16(5):1353-7. PubMed ID: 16325401
[TBL] [Abstract][Full Text] [Related]
15. CDK2/cyclinA inhibitors: targeting the cyclinA recruitment site with small molecules derived from peptide leads.
Castanedo G; Clark K; Wang S; Tsui V; Wong M; Nicholas J; Wickramasinghe D; Marsters JC; Sutherlin D
Bioorg Med Chem Lett; 2006 Mar; 16(6):1716-20. PubMed ID: 16384702
[TBL] [Abstract][Full Text] [Related]
16. Design of new benzoxazole-2-thione-derived inhibitors of Streptococcus pneumoniae hyaluronan lyase: structure of a complex with a 2-phenylindole.
Rigden DJ; Botzki A; Nukui M; Mewbourne RB; Lamani E; Braun S; von Angerer E; Bernhardt G; Dove S; Buschauer A; Jedrzejas MJ
Glycobiology; 2006 Aug; 16(8):757-65. PubMed ID: 16638841
[TBL] [Abstract][Full Text] [Related]
17. 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity.
Wang S; Meades C; Wood G; Osnowski A; Anderson S; Yuill R; Thomas M; Mezna M; Jackson W; Midgley C; Griffiths G; Fleming I; Green S; McNae I; Wu SY; McInnes C; Zheleva D; Walkinshaw MD; Fischer PM
J Med Chem; 2004 Mar; 47(7):1662-75. PubMed ID: 15027857
[TBL] [Abstract][Full Text] [Related]
18. Structure-based design of P3 moieties in the peptide mimetic factor VIIa inhibitor.
Kadono S; Sakamoto A; Kikuchi Y; Oh-eda M; Yabuta N; Yoshihashi K; Kitazawa T; Suzuki T; Koga T; Hattori K; Shiraishi T; Haramura M; Kodama H; Ono Y; Esaki T; Sato H; Watanabe Y; Itoh S; Ohta M; Kozono T
Biochem Biophys Res Commun; 2005 Feb; 327(2):589-96. PubMed ID: 15629154
[TBL] [Abstract][Full Text] [Related]
19. Prediction of multiple binding modes of the CDK2 inhibitors, anilinopyrazoles, using the automated docking programs GOLD, FlexX, and LigandFit: an evaluation of performance.
Sato H; Shewchuk LM; Tang J
J Chem Inf Model; 2006; 46(6):2552-62. PubMed ID: 17125195
[TBL] [Abstract][Full Text] [Related]
20. The discovery of N-(1,3-thiazol-2-yl)pyridin-2-amines as potent inhibitors of KDR kinase.
Bilodeau MT; Rodman LD; McGaughey GB; Coll KE; Koester TJ; Hoffman WF; Hungate RW; Kendall RL; McFall RC; Rickert KW; Rutledge RZ; Thomas KA
Bioorg Med Chem Lett; 2004 Jun; 14(11):2941-5. PubMed ID: 15125964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
